Rituximab in idiopathic nephrotic syndrome: still waiting for stronger evidences

J Bras Nefrol. 2023 Jul-Sep;45(3):274-276. doi: 10.1590/2175-8239-JBN-2023-E012en.
[Article in English, Portuguese]
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Immunosuppressive Agents
  • Nephrosis, Lipoid*
  • Nephrotic Syndrome* / drug therapy
  • Recurrence
  • Rituximab / therapeutic use
  • Treatment Outcome

Substances

  • Rituximab
  • Immunosuppressive Agents

Supplementary concepts

  • Nephrosis, congenital